Which has preferable earnings and valuation, FULC or NBTX?

Nanobiotix has lower revenue, but higher earnings than Fulcrum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulcrum Therapeutics $80M 2.68 -$74.88M -$1.15 N/A Nanobiotix $36.87M 46.32 -$27.11M N/A N/A

Is FULC or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -27.80% -26.32% Nanobiotix N/A N/A N/A

Does the media favor FULC or NBTX?

In the previous week, Fulcrum Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.22 beat Fulcrum Therapeutics' score of -0.58 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Negative Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FULC or ZYME?

In the previous week, Fulcrum Therapeutics had 15 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.59 beat Fulcrum Therapeutics' score of -0.58 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Negative Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FULC or IOVA?

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 22 mentions for Iovance Biotherapeutics and 19 mentions for Fulcrum Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.29 beat Fulcrum Therapeutics' score of -0.58 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Negative Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulcrum Therapeutics (FULC) Competitors

$3.22 +0.08 (+2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 -0.04 (-1.09%)

As of 07:15 PM Eastern

Compare

FULC vs. NBTX, NRIX, ZYME, IOVA, and HRMY

Should you buy Fulcrum Therapeutics stock or one of its competitors? MarketBeat compares Fulcrum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulcrum Therapeutics include Nanobiotix (NBTX), Nurix Therapeutics (NRIX), Zymeworks (ZYME), Iovance Biotherapeutics (IOVA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

How does Fulcrum Therapeutics compare to Nanobiotix?

Fulcrum Therapeutics (NASDAQ:FULC) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Nanobiotix	N/A	N/A	N/A

In the previous week, Fulcrum Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.22 beat Fulcrum Therapeutics' score of -0.58 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix has lower revenue, but higher earnings than Fulcrum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.68	-$74.88M	-$1.15	N/A
Nanobiotix	$36.87M	46.32	-$27.11M	N/A	N/A

Fulcrum Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 154.66%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 24.24%. Given Fulcrum Therapeutics' higher probable upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Nanobiotix beats Fulcrum Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Nurix Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Fulcrum Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.68	-$74.88M	-$1.15	N/A
Nurix Therapeutics	$83.98M	19.06	-$264.46M	-$3.16	N/A

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fulcrum Therapeutics had 18 more articles in the media than Nurix Therapeutics. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Fulcrum Therapeutics' score of -0.58 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Negative
Nurix Therapeutics	Very Positive

Fulcrum Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Fulcrum Therapeutics' return on equity of -27.80% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 154.66%. Nurix Therapeutics has a consensus target price of $30.46, indicating a potential upside of 96.78%. Given Fulcrum Therapeutics' higher probable upside, equities analysts clearly believe Fulcrum Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Fulcrum Therapeutics beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Zymeworks?

Fulcrum Therapeutics (NASDAQ:FULC) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Fulcrum Therapeutics had 15 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.59 beat Fulcrum Therapeutics' score of -0.58 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulcrum Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Fulcrum Therapeutics' return on equity of -27.80% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Zymeworks	-126.92%	-37.97%	-25.31%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Fulcrum Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 154.66%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 56.06%. Given Fulcrum Therapeutics' higher possible upside, equities research analysts clearly believe Fulcrum Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Fulcrum Therapeutics has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.68	-$74.88M	-$1.15	N/A
Zymeworks	$105.96M	16.78	-$81.13M	-$1.37	N/A

Summary

Zymeworks beats Fulcrum Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Iovance Biotherapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Fulcrum Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 154.66%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 122.39%. Given Fulcrum Therapeutics' higher probable upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fulcrum Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.68	-$74.88M	-$1.15	N/A
Iovance Biotherapeutics	$263.50M	6.42	-$390.98M	-$0.95	N/A

Fulcrum Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 22 mentions for Iovance Biotherapeutics and 19 mentions for Fulcrum Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.29 beat Fulcrum Therapeutics' score of -0.58 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative
Iovance Biotherapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Fulcrum Therapeutics' return on equity of -27.80% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Summary

Fulcrum Therapeutics and Iovance Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market.

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.14	$158.69M	$2.48	12.93
Fulcrum Therapeutics	$80M	2.68	-$74.88M	-$1.15	N/A

In the previous week, Fulcrum Therapeutics had 18 more articles in the media than Harmony Biosciences. MarketBeat recorded 19 mentions for Fulcrum Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat Fulcrum Therapeutics' score of -0.58 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Positive
Fulcrum Therapeutics	Negative

Harmony Biosciences currently has a consensus target price of $40.89, indicating a potential upside of 27.51%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 154.66%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Harmony Biosciences has a net margin of 16.20% compared to Fulcrum Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Summary

Harmony Biosciences beats Fulcrum Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$214.55M	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-2.80	17.93	22.29	24.19
Price / Sales	2.68	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	0.50	6.63	9.84	6.72
Net Income	-$74.88M	$24.20M	$3.57B	$337.19M
7 Day Performance	-52.51%	-3.24%	-1.17%	0.48%
1 Month Performance	-56.28%	0.53%	3.84%	5.06%
1 Year Performance	-54.20%	47.24%	27.39%	34.27%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	2.1006 of 5 stars	$3.22 +2.5%	$8.20 +154.7%	-54.9%	$214.55M	$80M	N/A	100	Trending News Analyst Downgrade High Trading Volume
NBTX Nanobiotix	2.1917 of 5 stars	$36.34 -4.4%	$26.67 -26.6%	+789.2%	$1.84B	$29.64M	N/A	100	Short Interest Increase Gap Down
NRIX Nurix Therapeutics	2.8828 of 5 stars	$16.40 -5.7%	$30.46 +85.8%	+34.8%	$1.84B	$71.78M	N/A	300
ZYME Zymeworks	2.5532 of 5 stars	$24.13 -1.7%	$38.00 +57.5%	N/A	$1.84B	$81.26M	N/A	460	Analyst Forecast High Trading Volume
IOVA Iovance Biotherapeutics	2.909 of 5 stars	$4.10 +3.4%	$8.43 +105.8%	+132.7%	$1.83B	$285.61M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. NBTX, NRIX, ZYME, IOVA, and HRMY

How does Fulcrum Therapeutics compare to Nanobiotix?

Summary

How does Fulcrum Therapeutics compare to Nurix Therapeutics?

Summary

How does Fulcrum Therapeutics compare to Zymeworks?

Summary

How does Fulcrum Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Fulcrum Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. NBTX, NRIX, ZYME, IOVA, and HRMY

How does Fulcrum Therapeutics compare to Nanobiotix?

Which has more risk and volatility, FULC or NBTX?

Is FULC or NBTX more profitable?

Does the media favor FULC or NBTX?

Which has preferable earnings and valuation, FULC or NBTX?

Do analysts prefer FULC or NBTX?

Do institutionals and insiders hold more shares of FULC or NBTX?

Summary

How does Fulcrum Therapeutics compare to Nurix Therapeutics?

Which has more volatility & risk, FULC or NRIX?

Which has higher valuation & earnings, FULC or NRIX?

Do insiders & institutionals believe in FULC or NRIX?

Does the media prefer FULC or NRIX?

Is FULC or NRIX more profitable?

Do analysts rate FULC or NRIX?

Summary

How does Fulcrum Therapeutics compare to Zymeworks?

Does the media favor FULC or ZYME?

Is FULC or ZYME more profitable?

Do insiders and institutionals have more ownership in FULC or ZYME?

Which has more volatility and risk, FULC or ZYME?

Do analysts rate FULC or ZYME?

Which has stronger earnings & valuation, FULC or ZYME?

Summary

How does Fulcrum Therapeutics compare to Iovance Biotherapeutics?

Do analysts prefer FULC or IOVA?

Do institutionals & insiders believe in FULC or IOVA?

Which has higher valuation and earnings, FULC or IOVA?

Which has more volatility & risk, FULC or IOVA?

Does the media prefer FULC or IOVA?

Is FULC or IOVA more profitable?

Summary

How does Fulcrum Therapeutics compare to Harmony Biosciences?

Which has more risk & volatility, HRMY or FULC?

Do insiders & institutionals believe in HRMY or FULC?

Which has stronger earnings and valuation, HRMY or FULC?

Does the media favor HRMY or FULC?

Do analysts rate HRMY or FULC?

Is HRMY or FULC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools